BlackRock Fund Advisors - HTG MOLECULAR DIAGNOSTICS IN ownership

HTG MOLECULAR DIAGNOSTICS IN's ticker is HTGM and the CUSIP is 40434H104. A total of 22 filers reported holding HTG MOLECULAR DIAGNOSTICS IN in Q3 2015. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
BlackRock Fund Advisors ownership history of HTG MOLECULAR DIAGNOSTICS IN
ValueSharesWeighting
Q4 2016$4,000
+100.0%
1,621
+50.0%
0.00%
Q3 2016$2,000
-33.3%
1,081
+15.4%
0.00%
Q2 2016$3,000
-90.0%
937
-91.1%
0.00%
Q1 2016$30,000
-38.8%
10,518
-7.0%
0.00%
Q4 2015$49,000
-40.2%
11,304
+5.4%
0.00%
Q3 2015$82,000
-26.1%
10,726
+7.9%
0.00%
Q2 2015$111,0009,9430.00%
Other shareholders
HTG MOLECULAR DIAGNOSTICS IN shareholders Q3 2015
NameSharesValueWeighting ↓
Novo Holdings A/S 1,280,185$9,755,0001.01%
Cormorant Asset Management, LP 201,000$1,532,0000.24%
PUTNAM INVESTMENTS LLC 575,692$4,386,0000.01%
Alyeska Investment Group, L.P. 114,113$870,0000.01%
VANGUARD GROUP INC 4,355,424$131,473,0000.01%
BLACKROCK ADVISORS LLC 463,200$3,530,0000.00%
OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) 26,100$199,000,0000.00%
Ironwood Financial, llc 870$7,0000.00%
PANAGORA ASSET MANAGEMENT INC 24,293$185,0000.00%
Sonora Investment Management, LLC 500$3,0000.00%
View complete list of HTG MOLECULAR DIAGNOSTICS IN shareholders